Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
Gregory Oakes has a proven track record of building and leading organizations across multiple therapeutic areas and geographies and has extensive launch and US Market Access experience. He joins from Amgen where he served as Corporate Vice President, Global Integration Lead for Otezla. In this role, he led the integration and commercialization of the $2B brand and successfully positioned it for sustained growth.
Prior to Amgen, Greg was Corporate Vice President and US General Manager at Celgene and previously held several executive positions at Novartis in the US. He began his career at Schering-Plough (Merck) where he worked in executive roles both in the US and Europe.
He received a Master of Business Administration (MBA) from Clemson University and a Bachelor of Science (BS) in Marketing and Business Administration from Edinboro University, both in the US.
Gregory Oakes succeeds Patrick Treanor who joined Relypsa in 2015 to establish the sales organisation for the US launch of Veltassa®. For the past two years as President US, Patrick was instrumental in leading the commercialisation strategy of Veltassa® and aiding Vifor in the integration of Relypsa towards our goal of becoming the leader in nephrology and cardio-renal therapies. Patrick has decided for personal reasons to pursue opportunities outside of Vifor Pharma.
Stefan Schulze, CEO of Vifor Pharma Group comments; “We are delighted that Gregory will join Vifor Pharma as President North America. He has a proven track record of overseeing highly successful acquisitions, growing product portfolios across multiple therapeutic areas and brings a wealth of commercialisation experience. We look forward to working with him to successfully drive and execute our ambitious growth plans in the US.
We would like to take this opportunity to thank Patrick for his dedicated leadership and outstanding contributions to our success over the past 5 years. Patrick played a pivotal role in the success and integration of Relypsa and we wish him the very best for his future endeavours, both professionally and personally.”
Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BearingPoint: Organizations That Invest in Frontline Managerial Skills Are More Resilient and Adaptable Than Competitors25.11.2020 08:57:00 CET | Press release
The Covid-19 pandemic has shown that organizations that invest in frontline managerial skills are more resilient and adaptable than competitors. Frontline managers initiate process improvements and new ways of working. According to a recent study by the BearingPoint Institute, the research arm of management and technology consultancy BearingPoint, company leaders must make frontline managers a driving force for change to ensure transformation success and adapt to market changes. "With transformational pressures exerting themselves on business, frontline managers have never been more crucial to organizations. Our study shows how important it is to develop, empower and unleash the skills, enthusiasm, and innovation of these leaders. It is the only way to get the most out of digitalization and quickly adapt to the continuously changing market. Investing in frontline management will not only mean continuing success, but it will help you identify and hone tomorrow's leaders," says André Est
European Commission Approves Janssen’s TREMFYA ® ▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)25.11.2020 08:00:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved TREMFYA®▼ (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Guselkumab is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. It is already approved for the treatment of patients with moderate to severe plaque psoriasis. IL-23 is an important driver of the progression of inflammatory diseases including psoriasis and PsA, among others.1 PsA is a multifaceted, chronic, immune-mediated inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis
Universal Peace Federation: 70 Years After the Korean War World Leaders Call for Peace at Online Rally of Hope24.11.2020 19:19:00 CET | Press release
Millions of viewers tuned into hundreds of broadcast stations and gathered online to call for peace among and between nations at the third Rally of Hope sponsored by the Universal Peace Federation (UPF) in Korea on Sunday, Nov. 22. UPF was founded in 2005 by Rev. Dr. Sun Myung Moon and Dr. Hak Ja Han Moon and is an NGO in General Consultative Status with the United Nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005906/en/ Dr. Hak Ja Han Moon addresses live audience and online participants from all around the world at the Rally of Hope (Photo: Business Wire) Mrs. Moon announced two new projects: to set up Korean War memorials in those nations that do not yet have them and create an online registry of all those who sacrificed in any way to support Korea during its darkest hour. “All around the world, unforeseen and unexpected challenges are erupting in the realms of politics, economy and religion” she said. “We
Verimatrix Chief Revenue Officer Named to SportsPro OTT Summit Advisory Board24.11.2020 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Lu Bolden, Chief Revenue Officer, was named to the SportsPro OTT Summit Advisory Board, the group that shapes one of world’s most prominent sports broadcasting annual events. The second annual event takes place December 2-3, 2020. Organized by SportsPro Media, this year’s virtual SportsPro OTT Summit is the preeminent venue for learning the latest in strategy, content and technology trends in the sports broadcasting market. The OTT Summit Advisory Board reads as a who’s who of the digital sports broadcasting realm, including executives from the UFC, NFL, MotoGP, Fox Sports, DAZN, PGA Tour, Canal+, Formula One, NBC Sports and the International Olympic Committee. Bolden brings to the group the needed expertise in how to easily deliver excellent fan experiences on any device while also securely scaling during popular live eve
ender diagnostics Receives FDA Notification for Rapid and Reliable COVID-19 Tests24.11.2020 15:41:00 CET | Press release
The two ender COVID-19 tests received the FDA notification, marking the entry of the Swiss company into the US market. With the continued surge of COVID-19 cases in the US, the American subsidiary of ender diagnostics, ENDER DIAGNOSTICS NORTH AMERICA, is ready to deliver rapid and reliable COVID-19 testing kits to diagnostic laboratories wishing to increase their testing capacities. The company is proud to be actively contributing to successfully manage the pandemic. The ender products are highly accurate and fast, allowing laboratories to increase their throughput significantly. ender LAB and ender MASS arein-vitro diagnostic test kits based on a rapid molecular isothermal nucleic acid amplification technology. Both ender LAB and ender MASS are designed for use by laboratory professionals or trained operators on standard real-time PCR devices. For ender LAB, the result is provided within 30 minutes after the extraction of the viral RNA, which makes it significantly faster than typical
LBC Tank Terminals Holding Netherlands B.V. Announces Q1 FY21 Financial Results Conference Call24.11.2020 15:06:00 CET | Press release
LBC Tank Terminals announced today that a conference call will be held to discuss the company’s financial results for Q1 FY21 which ended on 30 September 2020. The results will be published today, Tuesday 24 November 2020, followed by a conference call for all investors on Tuesday, 1 December 2020 at 16:00 (Central European Time) / 10:00 (Eastern Standard Time). Call details and copies of the financial statements will be made available on the Intralinks website. Investors of LBC Tank Terminals Holding Netherlands B.V. Senior Notes, due 2023, can request access to Intralinks by contacting email@example.com. LBC Tank Terminals LBC Tank Terminals, with its headquarter in Belgium, is an independent operator of midstream and downstream bulk liquid storage facilities for chemicals, oils and refined petroleum products currently owning and operating seven terminals located in Houston, Freeport, Baton Rouge, Antwerp and Rotterdam with combined storage capacity of 2.6 million m³, serving over